2015 Apr 25. pii: S0960-894X(15)00387-X. doi: 10.1016/j.bmcl.2015.04.055. [Epub ahead of print]
Saccomanni G1, Pascali G2, Carlo SD1, Panetta D3, De Simone M3, Bertini S1, Burchielli S4, Digiacomo M1, Macchia M1, Manera C5, Salvadori PA3.
Abstract
In the present work, we report the synthesis of new aryliodonium salts used as precursors of single-stage nucleophilic 18F radiofluorination. The corresponding unlabelled fluorinated derivatives showed to be CB2 cannabinoid receptor specific ligands, with Ki values in the low nanomolar range and high CB2/CB1 selectivity. The radiolabelled compound [18F]CB91, was successfully formulated for in vivo administration, and its preliminary biodistribution was assessed with microPET/CT. This tracer presented a reasonable in vivo stability and a preferential extraction in the tissues that constitutionally express CB2 cannabinoid receptor. The results obtained indicate [18F]CB91 as a possible candidate marker of CB2 cannabinoidreceptor distribution. This study would open the way to further validation of this tracer for assessing pathologies for which the expression of this receptor is modified.
Copyright © 2015. Published by Elsevier Ltd.
Copyright © 2015. Published by Elsevier Ltd.
KEYWORDS:
CB2 receptor; Cannabinoid; Iodonium derivatives; Microfluidic system; Radiofluorination
- PMID:
- 25956416
- [PubMed – as supplied by publisher]